Search Results

You are looking at 1 - 10 of 22 items for :

  • "dermatologist" x
  • Refine by Access: All x
Clear All
Full access

Allan C. Halpern and Sanjay K. Mandal

malignant melanoma by dermatologists of the American Academy of Dermatology. II. Definitive surgery for malignant melanoma . J Am Acad Dermatol 1995 ; 33 : 451 – 461 . 11. Armstrong BK Kricker A . The epidemiology of UV induced skin cancer

Full access

Tejaswi Mudigonda, Daniel J. Pearce, Brad A. Yentzer, Phillip Williford, and Steven R. Feldman

treatment is provided in hospitals, ambulatory/outpatient surgical centers, and physician offices. NMSC is most commonly treated in the United States by dermatologists, although plastic surgeons, otolaryngologists, facial plastic surgeons, general surgeons

Full access

Shoko Mori, Cristian Navarrete-Dechent, Tatyana A. Petukhova, Erica H. Lee, Anthony M. Rossi, Michael A. Postow, Lara A. Dunn, Benjamin R. Roman, Vivian T. Yin, Daniel G. Coit, Travis J. Hollmann, Klaus J. Busam, Kishwer S. Nehal, and Christopher A. Barker

% indicated the leaders were from a single specialty. The distribution of the clinical specialties for group leaders is shown in Figure 1 . Medical and surgical oncologists together constituted half of the meeting leaders. Dermatologists, including

Full access

Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz, and Sharon Spencer

This NCCN Task Force Report describes the management of dermatologic and ocular toxicities that occur in patients treated with epidermal growth factor receptor (EGFR) inhibitors. Task force members are from NCCN member institutions and include oncologists, dermatologists, an ophthalmologist, and a mid-level oncology provider. This report describes commonly used therapies that the task force agreed are appropriate standards of care for dermatologic and ophthalmologic toxicities associated with EGFR inhibitors, which generally are supported only by anecdotal evidence. Few recommendations are evidence based; however, some commonly used therapies have data supporting their use. Conclusions from completed clinical trials are generally limited by the small numbers of patients enrolled. The information in this report is based on available published data on treating toxicities associated with EGFR inhibitors, data from treatment of clinically similar toxicities from different etiologies, and expert opinion among the NCCN Task Force members.

Full access

Mario E. Lacouture

. Although referral to dermatologists is ideal, timely appointments are not always possible. At Memorial Sloan Kettering Cancer Center, Dr. Lacouture said, “We have tried to mitigate this delay through a referral system in which the oncology provider

Full access

Jennifer L. Schwartz, Sandra L. Wong, Scott A. McLean, James A. Hayman, Christopher D. Lao, Jeffrey H. Kozlow, Kelly M. Malloy, Carol R. Bradford, Marcus L. Frohm, Douglas R. Fullen, Lori Lowe, and Christopher K. Bichakjian

requires involvement of multiple specialists, including pathologists, dermatologists, surgeons, and radiation and medical oncologists. The impact of this multidisciplinary approach reaches beyond coordinated care. Within the framework of evidence

Full access

90th percentile for both. Anyone, at any age, should feel comfortable asking their dermatologist about a biopsy if they have a bump or flaky spot on their skin that lasts more than six-to-eight weeks or seems to be changing.” NCCN Guidelines for

Full access

James Saller, Christine M. Walko, Sherri Z. Millis, Evita Henderson-Jackson, Rikesh Makanji, and Andrew S. Brohl

evaluated at >90%. These findings were interpreted as consistent with KS. Of note, the patient reported that he was diagnosed with KS of the lower extremities by a dermatologist Figure 1. Tumor specimen pathologically consistent with Kaposi sarcoma

Full access

Daniel G. Coit

oncologists, dermatologists, radiologists, and pathologists, gathered together in a room in New York City, in a group chaired by Alan Houghton, MD, and overseen by Rodger Winn, MD. The stated mission of the then-fledgling organization, the National

Full access

Justin Famoso, Gerald Lemole, Srinath Sundararajan, and Baldassarre Stea

immunohistochemistry results (2+) for PD-L1, 70%. In addition, a pathogenic somatic mutation was identified in BAP1 on exon 11. The patient underwent systemic staging, including MRI total spine, total-body PET/CT, and complete skin survey by a dermatologist. All